Lake Street raised the firm’s price target on Cellebrite to $17 from $13.50 and keeps a Buy rating on the shares. Inseyets adoption has been better than expected, and the company now expects to convert 15% of the installed base in 2024, the analyst tells investors in a research note. Cellebrite also posted upside to revenue and AEBITDA for Q2 and guided above for both Q3 and 2024, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT: